Journal
INFLAMMATORY BOWEL DISEASES
Volume 28, Issue 11, Pages 1687-1695Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/ibd/izab339
Keywords
inflammatory bowel disease; COVID-19; global; temporal
Categories
Funding
- Helmsley Charitable Trust [2003-04445]
- National Center for Advancing Translational Sciences [UL1TR002489]
- Pfizer
- Takeda
- Janssen
- AbbVie
- Lilly
- Genentech
- Boehringer Ingelheim
- Bristol Myers Squibb
- Celtrion
- Arenapharm
- Canadian Institutes of Health Research [VR5-172684]
- [T32DK007634]
- [K23KD111995-01A1]
Ask authors/readers for more resources
The reporting of COVID-19 in inflammatory bowel disease (IBD) patients shows temporal trends that are consistent with the global epidemiological patterns of COVID-19.
Background Cases of coronavirus disease 2019 (COVID-19) have emerged in discrete waves. We explored temporal trends in the reporting of COVID-19 in inflammatory bowel disease (IBD) patients. Methods The Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) is an international registry of IBD patients diagnosed with COVID-19. The average percent changes (APCs) were calculated in weekly reported cases of COVID-19 during the periods of March 22 to September 12, September 13 to December 12, 2020, and December 13 to July 31, 2021. Results Across 73 countries, 6404 cases of COVID-19 were reported in IBD patients. COVID-19 reporting decreased globally by 4.2% per week (95% CI, -5.3% to -3.0%) from March 22 to September 12, 2020, then climbed by 10.2% per week (95% CI, 8.1%-12.3%) from September 13 to December 12, 2020, and then declined by 6.3% per week (95% CI, -7.8% to -4.7%). In the fall of 2020, weekly reporting climbed in North America (APC, 11.3%; 95% CI, 8.8-13.8) and Europe (APC, 17.7%; 95% CI, 12.1%-23.5%), whereas reporting was stable in Asia (APC, -8.1%; 95% CI, -15.6-0.1). From December 13, 2020, to July 31, 2021, reporting of COVID-19 in those with IBD declined in North America (APC, -8.5%; 95% CI, -10.2 to -6.7) and Europe (APC, -5.4%; 95% CI, -7.2 to -3.6) and was stable in Latin America (APC, -1.5%; 95% CI, -3.5% to 0.6%). Conclusions Temporal trends in reporting of COVID-19 in those with IBD are consistent with the epidemiological patterns COVID-19 globally.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available